Company / Free Cash Flow
Alaunos Therapeutics, Inc. Free Cash Flow History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$5.0M
FY2025
5-year range
-$66.8M / -$5.0M
FY2021-FY2025
Trend
+83.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has fluctuated over the past 10 years, ranging from -$67M in FY2021 to -$5M in FY2025.
Based on SEC 10-K filings.
-$5M in FY2025.
Improved from -$29M to -$5M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 83.6% year-over-year.
- Lowest free cash flow in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.0M | +83.6% |
| FY2024 | -$30.3M | -3.0% |
| FY2023 | -$29.4M | +54.5% |
| FY2022 | -$64.8M | +3.0% |
| FY2021 | -$66.8M | -33.8% |
| FY2020 | -$49.9M | +9.9% |
| FY2019 | -$55.4M | +5.9% |
| FY2018 | -$58.9M | -47.2% |
| FY2013 | -$40.0M | -101.2% |
| FY2012 | -$19.9M | -61.6% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026